In his third Reith lecture, Rutger Bregman argues for a new 'realist utopia' in the face of rapid technological change. He advocates fairer taxation and for tech to be regulated. Show more Dutch ...
This is not the finest hour for human rights, says 2025 CBC Massey Lecturer Alex Neve. But it still could be. The Universal Declaration of Human Rights was created 1948, after the untold carnage and ...
I never dreamed I’d end up 100-plus years old, but here I am still pumping out stories. I just turned 101 in September. Ask The Post AIDive deeper People always ask me, “What’s your longevity secret?” ...
AllRock Bio raised $50 million to advance Roc-101, a pan-ROCK inhibitor for PAH and ILD-PH, addressing disease-associated remodeling. Roc-101 complements existing therapies, with Phase 2a ROCSTAR ...
It’s the first week of school and you’re on top of your game. 9:30 a.m. lecture? Nothing. Discussion is cancelled? Shoot — you were all ready. You are so eager to start this new semester, and nothing ...
The government has registered 101 more biostimulants this week under the Fertiliser Control Order (FCO) taking the total notified formulations to 146. Through the extraordinary gazette notifications ...
Shares of Mustang Bio (NASDAQ:MBIO) jumped on Monday after the company said that the U.S. FDA has granted orphan drug status to its CAR T-cell therapy, MB-101, for the treatment of astrocytoma and ...
Mustang Bio Inc (NASDAQ:MBIO) shares are trading sharply higher Monday afternoon. The company earlier saw a positive development as the FDA granted Orphan Drug Designation to its cell therapy ...
Mustang Bio, Inc. announced that its IL13Ra2-targeted CAR T-cell therapy, MB-101, received Orphan Drug Designation from the FDA for treating recurrent diffuse and anaplastic astrocytomas and ...
WORCESTER, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical ...
Syntis Bio, a startup aiming to bring patients a key benefit of gastric bypass surgery but in the form of a pill, has raised $33 million as its lead program continues early clinical development as a ...
A California-startup focused on genetically editing human embryos — a step toward creating so-called designer babies — is raising money as many of Silicon Valley’s ultra-rich turn their attention to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback